Published • loading... • Updated
US FDA approves Revolution Medicines' pancreatic cancer drug
The once-daily pill cut death risk by 60% in a 500-patient trial and is the first drug to broadly target RAS mutations.
- On Aug 26, The FDA approved Rasonque, a new drug from Revolution Medicines for adults with advanced pancreatic cancer who have received prior treatment.
- Designed as a once-daily pill, Rasonque functions by blocking several forms of the RAS protein, which drives tumor growth in pancreatic cancer.
- Data from a study of 500 adults showed the drug improved median overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
- Andrew Ko, a medical oncologist at the University of California, San Francisco, called it "the biggest development we've had in pancreas cancer in decades."
- Revolution did not immediately respond to a request from Reuters for comment on the drug's pricing and availability following the regulatory clearance.
Insights by Ground AI
Podcasts & Opinions
328 Articles
328 Articles
The FDA has approved daraxonrasib, which in one study increased patient survival time from 6.7 to 13.2 months.
·Budapest, Hungary
Read Full Article
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy August 26,...
·Ra'anana, Israel
Read Full Article
The FDA had previously granted Daraxonrasib the designation of "Innovative Therapy," and accelerated its review
·Los Angeles, United States
Read Full ArticleCoverage Details
Total News Sources328
Leaning Left50Leaning Right41Center151Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
L 21%
C 62%
R 17%
Factuality
To view factuality data please Upgrade to Premium
